ArticleOncotarget2017
Bevacizumab combined with chemotherapy for glioblastoma: a meta-analysis of randomized controlled trials.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Comparative efficacy of glioma treatment strategies: an umbrella review of meta-analyses.Annals of medicine · 2025Pooled it
- Anti-vascular endothelial growth factor in glioblastoma: a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2018Pooled it
- Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study.Neuro-oncology · 2020Trial
- Overcoming Chemoresistance in Glioblastoma: Mechanisms, Therapeutic Strategies, and Functional Precision Medicine.International journal of molecular sciences · 2026Review
- Glioblastoma zebrafish Avatars guide therapeutic decisions in a patient with gliosarcoma: a case report.Communications medicine · 2025Article
- Tumor heterogeneity and resistance in glioblastoma: the role of stem cells.Apoptosis : an international journal on programmed cell death · 2025Review
- Bevacizumab‑associated intracerebral hemorrhage in patients with malignant glioma.Molecular and clinical oncology · 2025Article
- Current approaches in glioblastoma multiforme immunotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Review
- Engineering antibody and protein therapeutics to cross the blood-brain barrier.Antibody therapeutics · 2022Review
- Recent Advances in Glioma Therapy: Combining Vascular Normalization and Immune Checkpoint Blockade.Cancers · 2021Review
- Targeting Glucose Metabolism of Cancer Cells with Dichloroacetate to Radiosensitize High-Grade Gliomas.International journal of molecular sciences · 2021Review
- Article
- Glioma Stem Cells as Immunotherapeutic Targets: Advancements and Challenges.Frontiers in oncology · 2021Review
- Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma.Pharmaceuticals (Basel, Switzerland) · 2020Review
- First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide.Journal of neuro-oncology · 2020Article
- Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series.CNS oncology · 2019Article
- EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma.Journal of neuro-oncology · 2019Article
- A case report of high-grade astroblastoma in a young adult.CNS oncology · 2019Article
- Identification of hub genes and pathways in glioblastoma by bioinformatics analysis.Oncology letters · 2019Article
- Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets.Frontiers in oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bevacizumab, as antibodies, were applied to inhibit tumor angiogenesis by preventing activation of vascular endothelial growth factor receptor. We analyzed four clinical trials, including 607 patients, to investigate the efficacy and safety of bevacizumab when combined with chemotherapy for the treatment of glioblastomas. Results demonstrated that bevacizumab when combined with chemotherapy improved progression-free survival (HR = 0.66; 95% CI 0.56-0.78;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.